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Objectives. This study sought to assess the cost-effectiveness of 
captopril therapy for survivors of myocardial infarction. 
Background. The recent randomized, controlled Survival and 
Ventricuiar Enlargement (SAVE) trial showed that eaptopril 
therapy improves survival in survivors of myocardial infarction 
with an ejection fraction <40%. The present ancillary study was 
designed to determine how the costs required to achieve this 
increase in survival compared with those of other medical inter- 
ventions. 
Methods. We developed a decision-analytic model to assess the 
cost-effectiveness of captopril therapy in 50- to 80-year old survi- 
vors of myocardial infarction with an ejection fraction _<40%. 
Data on costs, utilities (health.related quality of life weights) and 
4-year survival were obtained directly from the SAVE trial, and 
long-term survival was estimated using a Markov model. In one 
set of analyses, we assumed that the survival benefit associated 
with eaptoprii therapy would persist beyond 4 years (persistent- 
benefit analyses), whereas in another set we assumed that capto- 
pril therapy incurred costs but no survival benefit beyond 4 years 
(limited-benefit analyses). 
Results. In the limited-benefit analyses, the incremental cost- 
effectiveness of captopril therapy ranged from $3,600/quality. 
adjusted life-year for 80-year old patients to $60,800/quality.adjusted 
life-year for 50-year old patients. In the persistent-benefit analy- 
ses, incremental cost-effectiveness ratios ranged from $3,700 
to $10,400/quality-adjusted life-year, depending on age. The out- 
come was generally not sensitive to changes in estimates of 
variables when they were varied individually over wide ranges. 
In a "worst-ease" analysis, incremental cost.effectiveness ratios 
for captopril therapy remained favorable ($8,700 to $29,200/ 
quality-adjusted life-year) for 60- to 80-year old patients but 
were higher ($217,600/quality.adjusted life-year) for 50.year old 
patients. 
Conclusions. We conclude that the cost.effectiveness of 
captopril therapy for 50. to 80-year old survivors of myocar- 
dial infarction with a low ejection fraction compares fa- 
vorably with other interventions for survivors of myocardial 
infarction. 
(J Am CoU Cardiol 1995;26:914-9) 
Several types of medications, including beta-adrenergic block- 
ing, anticoagulant, antiplatelet and cholesterol-lowering 
agents, as well as rehabilitation regimens, have been found to 
improve survival of patients who have had a myocardial 
infarction (1-3). Certain of these therapies have been found to 
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e relatively cost-effective as well, yielding gains i  survival at 
a "reasonable" cost (4,5). Recently, the angiotensin-converting 
enzyme inhibitor captopril was added to the list of beneficial 
therapies: The Survival and Ventricular Enlargement (SAVE) 
trial (6), a randomized, controlled trial of c ptopril therapy in 
2,231 survivors of myocardial infarction with an ejection frac- 
tion _<40%, found that captopril improved survival at an 
average of 3.5 years by 19%. To assess the cost-effectiveness of 
captopril therapy after myocardial infarction, we developed a 
decision-analytic model incorporating resource utilization, sur- 
vival, and health-related quality of life data from the SAVE 
trial. 
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Table 1. Four-Year Survival in the Survival and Ventricular 
Enlargement (SAVE) Trial 
No. of Proportion Surviving (Kaplan-Meier) 
Age (yr) Pts 1 yr 2 yr 3 yr 4 yr 
Pts assigned to 
placebo 
<40* 29 0.9655 0.8966 0.8576 0.8576 
40-49 181 0.9105 0.8936 0.8733 0.8112 
50-59 248 0.9392 0.8897 0.8459 0.8174 
60-69 418 0.8752 0.7999 0.7556 0.6725 
->70 240 0.8125 11.745 0.6319 0.5539 
Total 1,116 0.8821 0.8257 0.778 0.7070 
Pts assigned to 
captopril 
<40* 51 0.9804 0.9404 0.8990 0.899(1 
40-49 132 0.9164 0.9010 0.8823 0.8428 
50-59 300 0.8996 0.8895 0.8521 0.7835 
60-69 390 0.9074 (/.8350 0.7981 0.7438 
>-70 242 0.8512 0.8054 0.7516 0.6582 
Total 1,115 0.8974 0.8556 0.8169 0.7551 
*Excluded from cost-effectiveness model because of small sample size. 
Methods  
Effectiveness of therapy. To model the ffectiveness of 
therapy, we developed a Markov model (7,8). Markov models 
have been used extensively in medical decision and cost- 
effectiveness analyses (9-14). In a Markov model, long-term 
prognosis is simulated by "following" a hypothetical cohort of 
patients (here, clinically similiar to those in the SAVE trial) 
through states of health and illness. By assigning costs and
quality of life adjustments for time spent in each state, the 
model calculates the average cost and the average number of 
years of life, adjusted for their quality (quality-adjusted life- 
years), for each strategy (here, captopril vs. placebo), and the 
incremental cost-effectiveness (additional cost/additional 
quality-adjusted life-year gained) of one strategy compared 
with another. 
Our model incorporated actual all-cause mortality data for 
years 1 to 4 for the captopril and placebo groups from all 2,231 
trial patients (Table 1). We smoothed these data and then fit 
Cox proportional hazard models to incorporate the effects of 
age and treatment and the interaction f age with ~treatment to 
yield survival estimates for ages 50, 60, 70 anct 80 years (Table 
2). We then developed separate cost-effectiveness models for 
ages 50, 60, 70 and 80 years. 
Survival beyond the fourth year was simulated in the 
Markov model, which distinguished between coronary heart 
disease-related mortality and other-cause mortality. Age- 
specific other-cause mortality rates were obtained from U.S. 
life tables and incorporated into the model by the method of 
Sonnenberg and Wong (15). Age-specific oronary heart dis- 
ease mortality rates for patients with a history of myocardial 
infarction were obtained from the Coronary Heart Disease 
Policy Model (16) and were adjusted for the disease severity of 
SAVE patients by using age-specific hazard multipliers. Be- 
cause the effectiveness of captopril therapy beyond 4 years is 
Table 2. Age-Specific All-Cause Mortality 
Proportion Surviving 
Age (yr) and Group 1 yr 2 yr 3 yr 4 yr 
50 
Captopril 0.934 0.902 0.874 0.828 
Placebo 0.927 0.894 0.863 0.813 
6O 
Captopril 0.906 0.863 0.825 0.763 
Placebo 0.889 0.839 0.794 0.724 
70 
Captopril 0.868 0.810 0.759 0.678 
Placebo 0.832 0.760 0.698 0.603 
80 
Captopril 0.817 0.739 0.673 0.573 
Placebo 0.751 0.651 0.570 0.454 
unknown, we developed two models for each age group. In the 
"limited-benefit" models, we conservatively assumed that mor- 
tality rates for the captopril and placebo groups would be 
equivalent after the fourth year. In the "persistent-benefit" 
models, we assumed that the average ratio of the hazard rates 
for captopril versus placebo in years 2 to 4 of the SAVE study 
would persist beyond the fourth year. 
Utilities. To incorporate health-related quality of life ad- 
justments into the analysis, we assessed time trade-off utilities 
(quality weights) (17) during the course of the SAVE trial from 
a sample of 82 study patients followed up at one study site, 
Brigham and Women's Hospital in Boston. The 82 patients 
were similar in age (mean age 60.3 years vs. 59.4 years in the 
SAVE trial) and gender (79% male vs. 82% male) to those in 
the overall SAVE trial. We assumed the utilities of the 82 
patients would apply to all trial patients, stratified by whether 
they were receiving captopril or placebo. 
The utility assessment has been described in detail previ- 
ously (18,19). Briefly, trained interviewers unaware of treat- 
ment status offered patients a choice between living 10 years in 
their current state of health or a shorter life in excellent health. 
The amount of time in excellent health was varied systemati- 
cally until a point of indifference was ascertained. A patient's 
time trade-off utility is calculated by dividing the number of 
years in excellent health by the number of years of current 
health at the indifference point. For example, if a patient is 
indifferent to living 8 more years in excellent health or 10 more 
years in his or her current state of health, then the utility for 
the current health state is 8/10, or 0.8. Utilities can range from 
0.0 to 1.0. 
Time trade-off utilities were assessed serially, beginning at a 
median of 12 months after myocardial infarction. The average 
time elapsed between the first and last assessments was 8.4 
months. As reported previously (19), time-trade-off scores did 
not change significantly between the first and last interviews 
(mean change 0.03, 95% confidence interval -0.02 to 0.08) 
and thus were assumed in our model to remain stable. 
Costs. The cost analysis was performed from the perspec- 
tive of the health care system using direct medical costs rather 
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than charges (20). Cost estimates for the model were based on 
actual resource utilization of trial patients. For all 123 patients 
followed up at Brigham and Women's Hospital with available 
data, we obtained detailed cardiac medication and hospital 
period data (from both Brigham and Women's Hospital and 
other hospitals). Reviewers who had no knowledge of treat- 
ment status assigned each hospital period a diagnosis-related 
group (DRG) reimbursement rate plus a physician fee based 
on the Resource-Based Relative Value Scale (RBRVS). The 
physician fee was calculated on the basis of average length of 
stay using the median reimbursement rate for the initial 
hospital day (Current Procedural Terminology [CPT] code 
99222), for each subsequent day (CPT 99232) and for the 
discharge day (CPT 99238). 
Each cardiac medication was assigned a wholesale acquisi- 
tion cost (21) plus a dispensing cost of $4.24/1-month supply, 
the average of three published rates (22-24). As with the 
utilities, the hospital stay and cardiac medication costs derived 
from patients followed up at one center were assumed to apply 
to the entire study cohort and were stratified by whether 
patients were receiving captopril or placebo. 
The costs of captopril therapy were based on the average 
daily dose in milligrams (as assessed by pill counts) of all 
SAVE trial patients assigned to captopril therapy and con- 
sisted of an acquisition cost of $0.0174/mg ($2.61/full dose of 
50 mg three times daily) (21) plus a dispensing cost of 
$4.24/1-month supply. To estimate costs of outpatient visits, we 
chose not to use the actual number of per-patient visits in the 
SAVE trial because we believed that trial patients were seen 
more often than might be expected in ordinary care (25). 
Instead, we assumed that each patient would have three 
"expected" outpatient visits plus the average number of un- 
scheduled interim visits in SAVE each year, stratified by 
whether they were receiving captopril or placebo. Each office 
visit was assigned the median RBRVS reimbursement for 
established patients (CPT 99213). Costs of outpatient ests 
were assumed to be equal under both strategies and were thus 
not modeled explicitly; to the extent that patients not receiving 
captopril therapy may have undergone more outpatient tests 
(e.g., electrocardiograms, echocardiograms, thallium stress 
tests), our analysis would be biased against the captopril 
strategy. 
All costs were converted to 199l U.S. dollars using the 
medical care component of the consumer price index. All costs 
and life-years were discounted at 5%/}'ear. Cost-effectiveness 
ratios, expressed as incremental cost per quality-adjusted 
life-year, were rounded to the nearest $100/quality-adjusted 
life-year. 
Sensitivity analyses. All survival benefit, utility and cost 
estimates were subjected individually to sensitivity analyses 
over wide ranges (Table 3) to determine whether theoutcome 
was affected. In addition, we performed a "worst case" analysis 
in which eaptopril therapy incurred costs but yielded no 
long-term survival benefit, lower utility and no savings in 
hospital costs, outpatient follow-up costs and costs of other 
Table 3. Costs and Utilities 
Base Case Estimates (range xamined in 
sensitivity analyses) 
Annual Direct Medical Cost Captopril Group Placebo Group 
Captopril therapy ($) 631 (0-1,000) 0 (NA) 
Other cardiac medications ($) 520 (0-1,500)* 531 (0-1,000)t 
Hospital 
1st yr ($) 5,950 (0-20,000)* 8,687 (0-10,000)~ 
Subsequent yr ($) 1.958 (0-20,000)* 2,298 (0-10,000)~ 
Outpatient visits ($) 139 (0-2,000)* 140 (0-500)? 
Utilities 0.88 (0-1.0)* 0.89 ( 0.05-0.05)t 
*In performing the sensitivity analyses on estimates for the captopril group, 
the difference b tween captopril and placebo group estimates was held constant; 
for example, the cost of other cardiac medications was varied from $0 to $1500 
and. for each value, the corresponding cost for the placebo group was $11 
($531 $520) greater. ?Sensitivity analysis ranges for the placebo group 
represent the costs or utilities in excess of the corresponding captopril group 
estimates: for example, the cost of other cardiac medications was varied from $0 
to $1J1181 more than the corresponding cost for the captopril group ($520). NA 
not applicable. 
medications. All analyses were performed using Decision 
Maker version 7.0 (Pratt Medical Group). 
Resu l ts  
Costs and utilities. The cost of captopril therapy, based on 
the average dose taken by patients in the SAVE trial plus 
dispensing fees, was calculated to be $631/year ($1.73/day) 
(Table 3). This cost was partially offset by savings in hospital 
costs and other cardiac medications. Estimated annual outpa- 
tient visit costs were similar for the two groups. Mean (+SD) 
utilities for patients taking captopril (0.88 _+ 0.22) were 
marginally but not statistically significantly lower than for 
patients not taking captopril (0.89 _+ 0.18). 
Baseline cost-effectiveness analyses. In the limited-benefit 
model, which conservatively assumed similar annual mortality 
rates with captopril therapy and placebo beyond the fourth 
year after myocardial infarction, the cost-effectiveness of cap- 
topril therapy improved with age, ranging from $60,800/ 
quality-adjusted life-year for 50-year old patients to $3,600/ 
quality-adjusted life-year for 80-year old patients (Table 4). In 
the persistent-benefit model, cost-effectiveness ratios were 
similar to those in the limited-benefit model for patients 60 to 
80 years old ($3,700 to 5,600/quality-adjusted life-year). For 
50-year old patients, who had the most years of life remaining 
in which potentially to benefit from captopril therapy, the 
cost-effectiveness ratio in the persistent-benefit model was 
substantially better ($10,400/quality-adjusted lif -year) than in 
the limited-benefit model. 
Sensitivity analyses. Limited-benefit analyses'. In general, 
the analyses for patients 60 to 80 years old were not sensitive 
to even large changes in baseline utilities, discount rates, 
hospital costs, cardiac medications and outpatient follow-up 
costs. For 50-year old patients, the results were sensitive to the 
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Table 4. Cost-Effectiveness of Captopril Therapy 
Average 
Cost Average Incremental C/E
Age (yr) and Strategy ($)*'~ QALYs* ($/QALY)*$ 
Limited-Benefit Model 
50 
No captopril 
Captopril 
60 
No captopril 
Captopril 
70 
No captopril 
Captopril 
80 
No captopril 
Captopril 
30,369 8.10 
32,098 8.13 60.800 
24,449 6.33 
26,128 6.51 9,000 
19,099 4.72 
20,822 5.07 4,900 
14.844 3.44 
16.699 3.96 3,600 
Persistent-Benefit Model 
50 
No captopril 30,369 8.10 
Captopril 32,883 8.34 10,400 
60 
No captopril 24,449 6.33 
Captopril 27,382 6.85 5,600 
70 
No captopril 19,099 4.72 
Captopril 22,292 5.47 4,300 
8O 
No captopril 14,844 3.44 
Captopril 18,067 4.33 3,700 
*Discounted at 5%/yr. ,Expressed in 1991 U.S. dollars. :[:Calculated as 
difference in average costs (captopril minus no captopril) divided by correspond- 
ing difference in average number of qualiw-adjusted life-years (QALYs), 
rounded to the nearest $100/quality-adjusted life-year. C/E - cost-effectiveness 
ratio (captopril vs. no captopril). 
annual cost of captopril therapy (baseline cost $631/year). If 
captopril therapy cost <$444/year, then this strategy was both 
more effective and less costly; but if it cost $1,000/year, the 
incremental cost-effectiveness ratio for captopril therapy in- 
creased to $180,800/quality-adjusted life-year. The outcome 
for 50-year old patients was also sensitive to the difference in 
utilities between the two strategies (baseline difference 0.01 
favoring no captopril). If the difference were 0.02 favoring no 
captopril, then the no-captopril strategy was both more effec- 
tive and less costly, whereas if the difference were 0.02 favoring 
captopril, then captopril therapy would cost $5,700/quality- 
adjusted life-year. 
Persistent-benefit analyses. In the persistent-benefit analy- 
ses, the outcome was most sensitive among 50-year old pa- 
tients, but incremental cost-effectiveness ratios were generally 
more stable than in the limited-benefit models. For example, 
increasing the cost of captopril therapy for 50-year-old patients 
to $1,000/year yielded an incremental cost-effectiveness ratio 
of $24,900/quality-adjusted life-year. The outcome was sensi- 
tive to the difference in utilities but less so than in the 
limited-benefit analyses. For 50-year old patients, a difference 
of 0.02 in the quality weight favoring captopril yielded an 
incremental cost-effectiveness ratio of $4,900/quality-adjusted 
life-year, whereas a similar difference favoring the no-captopril 
strategy yielded an incremental cost-effectiveness ratio of 
$16,700/quality-adjusted life-year. Savings associated with cap- 
topril therapy in the cost of other cardiac medications equaling 
$287/year (baseline savings $ ll/year) or in the cost of physician 
visits equaling $277/year (baseline savings $1/year) rendered 
the captopril therapy both less costly and more effective than 
the no-captopril strategy for 50-year old patients. 
"Worst case" analyses. When a "worst-case" scenario was 
assumed in which captopril therapy did not reduce the annual 
mortality rate after the fourth year after myocardial infarction 
and was not associated with any savings in hospital costs, other 
cardiac medications and physician follow-up visits and yet was 
associated with a 1% lower quality adjustment (utility), the 
cost-effectiveness of captopril therapy remained favorable in 
patients >60 years old. The incremental cost-effectiveness 
ratio for 50-year old patients was $217,600/quality-adjusted 
life-year. For 60-year old patients, it was $29,200/quality- 
adjusted life-year, whereas for 70- and 80-year old patients it 
was $13,700/quality-adjusted life-year and $8,700/quality- 
adjusted life-year, respectively. 
Discuss ion  
In an era of extensive change in health care, it is becoming 
incumbent among practitioners and policy makers to show that 
diagnostic tests and therapies are effective and, increasingly, 
cost-effective. The effectiveness of angiotensin-converting e - 
zyme therapy for survivors of myocardial infarction with left 
ventricular dysfunction has been demonstrated in several 
studies (6,26,27). The present study shows that captopril 
therapy after myocardial infarction is also relatively cost- 
effective compared with other commonly accepted therapies 
for patients with coronary heart disease (14,28-36) (Table 5). 
The present study complements a recent analysis (37) showing 
that therapy with another angiotensin-converting e zyme in- 
hibitor, enalapril, is relatively cost-effective for patients with 
congestive heart failure. 
Long-term e~ect of captopril. The effect of captopril ther- 
apy on survival >4 years is unknown. The implication for this 
analysis is that it is unclear whether the results of the "limited- 
benefit" analyses are more relevant than those of the 
"persistent-benefit" analyses, or vice versa. In the persistent- 
benefit assumption, the annual mortality rate for the captopril 
group continues to be lower than that for the placebo group, so 
that the gap between the survival curves widens. In the 
limited-benefit assumption, he mortality rates equalize after 4 
years, so that the survival curves mirror each other but do not 
merge or cross. Here, it is important o realize that although 
the (age-adjusted) life expectancy for each individual 4-year 
survivor is the same whether he or she is taking captopril or 
not, the captopril cohort will continue to accrue more life-years 
because more patients survived the initial 4 years. A third 
possibility (not considered) is that the survival curves for the 
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Table 5. Cost-Effectiveness of Various Interventions for Patients 
With Corona~ Heart Disease 
Intervention (ref no.) Incremental C/E 11991 $) 
Lovastatin 20 mg/d for secondary_ 
prevention (28) 
Smoking cessation program after acute 
myocardial infarction (29) 
Aspirin for acute myocardial 
infarction (30) 
Beta-blockers after myocardial 
infarction (31) 
Cardiac rehabilitation after myocardial 
infarction (32) 
Coronary artery bypass grafting for 
three-vessel or left main disease (33) 
Captopril after myocardial infarction 
Limited-benefit assumption 
Persistent-benefit assumption 
Percutaneous transluminal corona~, 
angioplasty for one- or two-vessel 
disease (14) 
Thrombolysis in elderly with suspected 
acute myocardial infarction (34) 
Thrombolysis with -PA vs. streptokinase 
(35) 
Coronary- care unit admission for patients 
with 5-2/1% probability of acute 
myocardial infarction (4.36) 
Cost saving $17,800/YOLS 
$220/YOLS 
$2,8011/YOLS 
$3 200-18,400/TOLS 
$6,800-9,200/QALY 
$21,800-35,900/YOLS 
$7,5011-16,400/QALY 
$3,600-611.SlXl/QAL Y 
$3,700-10,4(XJ/QALY 
$7,71X)-111.000/QALY 
$21,21XI-22.4011/YOLS 
$28,71/11 
$78,000-328,500/YOLS 
Costs converted to 1991 dollars using the medical component of thc 
consumer price index. C/E - cost-effectiveness ratio; QALY quality-adjusted 
life-years; t-PA - tissue-type plasminogen activator; YOLS year of life savcd. 
captopril and placebo groups could merge or even cross 
immediately or some time after the end of the 4-year follow- 
up. However, a sudden cessation of the benefit of captopril 
therapy after 4 years is clinically unlikely, particularly because 
the captopril and placebo survival curves in the SAVE trial 
were still separating at 4 years (Table 2). Furthermore, ex- 
tended follow-up analyses of patients completing the SAVE 
study support a persistent survival benefit from captopril 
therapy (Pfeffcr MA, Moy6 LA, Rouleau JL, Wun C-CC, 
Braunwald E, for the SAVE investigators, unpublished ata). 
In any case, discounting future life-years erves to mitigate the 
impact of any projection involving long-term survival. 
Sensitivity analysis. The outcome of the analysis was rel- 
atively unaffected by reasonable variations in most other 
assumptions. Except under very conservative assumptions in
50-year old patients, the incremental cost-effectiveness of 
captopril therapy compares favorably with analogous interven- 
tions. Of the many variables, the outcome was relatively 
dependent on only two. 
1. At least in the limited-benefit analysis for 50-year old 
patients, the outcome was sensitive to the cost of captopril 
therapy: At costs of captopril <$444/year, prescribing captopril 
would be both more ffective and less costly overall than 
withholding it; but at costs of $1,000/year, the incremental 
cost-effectiveness ratio for captopril therapy would be 
$180,800/quality-adjusted life-year. Although there is no uni- 
versally accepted threshold cost-effectiveness ratio (38), phar- 
maceutical companies might base medication pricing onresults 
of analyses uch as these or on qualitative thresholds (39) to 
ensure that their medication is included on formularies. Other 
factors, such as the impending availability of a generic formu- 
lation of captopril, might also affect its price. 
2. The outcome was sensitive to the quality weight (utility) 
associated with captopril versus placebo therapy. In our sam- 
ple, the time trade-off utility of patients taking captopril was 
slightly but not statistically significantly lower (worse) than for 
patients not taking captopril. Although conclusions are limited 
by sample size, our data provide evidence that a major 
deleterious effect from the intervention was most likely not 
present. Testa et al. (40) and Croog et al. (41) have shown that 
when used as an antihypertensive agent, captopril can have 
beneficial effects on health status. An explanation for the 
discrepancy is that utilities, which assess how subjects value 
their state of health, do not necessarily correlate with actual 
health status (18,19,42-49). 
An alternative xplanation is that the sample size for the 
utility assessment in the present s udy was small. In the full 
SAVE trial, captopril therapy was associated with a lower 
incidence of congestive heart failure (6). In another study of 
survivors of myocardial infarction, utilities of patients with 
congestive heart failure were approximately four percentage 
points lower than those for patients without congestive heart 
failure (Cleary PD, Guadagnoli E, personal communication, 
April, 1993). Thus, if utilities of patients taking captopril were 
actually the same as or higher than those of patients not taking 
captopril, then captopril therapy would be even more cost- 
effective. 
Study limitations. There are several caveats to this analy- 
sis. l) Eisenberg et al. (25) caution against applying costs 
obtained from a randomized, controlled trial to nontrial pa- 
tients: Trial patients may be treated and tested more aggres- 
sively (resulting in either greater or lesser costs in the long 
run); trial patients are carefully selected and may not be 
representative of ordinary patients; and trial patients have 
better compliance. Yet, sensitivity analyses showed that the 
outcome was not substantially altered even with large changes 
in baseline cost estimates. 2) Results from the present analyses 
should not be extrapolated topatients outside the age range of 
the present analyses. 3) Our analysis takes a societal rather 
than an individual patient's perspective. Therapeutic decisions 
for patients should consider the patient's own risks, benefits 
and preferences (50). 
Conclusions. Despite the previous limitations, angiotensin- 
converting enzyme inhibitor therapy with captopril is not only 
effective for survivors of myocardial infarction with a low 
ejection fraction, but also relatively cost-effective. Except when 
contraindicated, it should be added to the growing list of 
medical therapies for such patients. 
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